Because biased agonists can induce glucose uptake through selective activation of the PI3K/AKT pathway without mitogenic stimulation, they show the potential to alleviate the adverse effects of insulin administration or hyperinsulinemia. This evidence concerns the gene INS and hyperinsulinism.